Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional
ID: 352144Type: Posted
Overview

Buyer

Food and Drug Administration (HHS-FDA)

Award Range

$0 - $500K

Eligible Applicants

Others

Funding Category

Food and Nutrition

Funding Instrument

Cooperative Agreement

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352144
Timeline
  1. 1
    Forecast Posted Not available
  2. 2
    Forecast Due Not available
  3. 3
    Posted Jan 31, 2024 12:00 AM
  4. 4
    Due Apr 5, 2024 12:00 AM
Description

The Food and Drug Administration (FDA) has posted a grant opportunity titled "Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional". This grant aims to encourage new approaches in supporting therapeutic development for ultra-rare pediatric and adult cancers, including molecularly-defined subsets of more common cancers. The grant is a Cooperative Agreement and falls under the category of funding activity for Food and Nutrition. The funding amount for this opportunity is $500,000, with an expected number of awards being 1. The grant does not require cost sharing or matching. The eligibility criteria allow for foreign organizations and non-domestic entities to apply, including non-domestic components of U.S. organizations. The closing date for applications is April 5, 2024. For more information, interested parties can contact Zahara Graves at zahara.graves@fda.hhs.gov or call 240-402-0151.

Point(s) of Contact
zahara.graves@fda.hhs.gov
Files
No associated files provided.
Similar Opportunities
Drug Development Tools Research Grants (U01) Clinical Trials Optional
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering Drug Development Tools Research Grants (U01) through a Cooperative Agreement funding instrument. This opportunity falls under the category of Food and Nutrition and is currently open for applications. The grants aim to support the development of drug development tools that have an accepted or reviewable Letter of Intent (LOI) within the FDA's Drug Development Tool Qualification Program. These tools are intended to fill unmet needs in drug development and will be made publicly available once qualified. The grants do not require cost sharing or matching requirements. The estimated total program funding is $6 million, with an expected number of 6 awards to be granted. The award ceiling and floor are both set at $500,000. The closing date for applications is May 13, 2025, and the archive date is June 12, 2025. Eligible applicants include developers of drug development tools who have an accepted or reviewable LOI within the FDA's Drug Development Tool Qualification Program and are working towards their qualification plan or full qualification package. Previous recipients of DDT research grant support from FDA-CDER/CBER are also eligible to apply if they have successfully progressed to the next submission milestone and are requesting additional funding for new DDT project needs addressing different aspects of the project. For more information and to apply, please visit the following link: [RFA-FD-24-030 Funding Opportunity Announcement](https://grants.nih.gov/grants/guide/rfa-files/RFA-FD-24-030.html). If you have any questions, you can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov.
Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is announcing a Funding Opportunity Announcement (FOA) for a Cooperative Agreement titled "Identification and Evaluation of Possible Approaches to Addressing Nitrosamine Impurities in Drugs (U01)". This opportunity falls under the category of Food and Nutrition. The aim of this grant is to improve the safety of human drugs with potential nitrosamine impurity liabilities. The FDA is seeking proposals to conduct research, development, and refinement of translational and implementable practices that will protect the public against nitrosamine risks while ensuring continued safe access to critical therapeutic drugs. The grant recipient will also assess how best to ensure that this research and practices development continues among industry members, non-profits, and/or academic institutions once the FDA funding for this cooperative agreement ends. The grant amount for this opportunity is set at $350,000, with an expected number of awards being 1. There is no cost sharing or matching requirement for applicants. The eligible applicants are unrestricted, meaning any organization can apply. However, applicant organizations may submit more than one application, provided that each application is scientifically distinct. For more information and to apply, interested parties can contact Terrin Brown, the Grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610. The deadline for submission is November 30, 2023.
Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a federal grant opportunity titled "Improving Predictability of Food-Drug and Drug-Drug Interaction Risks by Utilizing In Vitro Simulated Gastrointestinal Dissolution Model for High-Risk Oral Drug Products (U01) Clinical Trial Optional". This funding opportunity falls under the category of Consumer Protection and is a Cooperative Agreement type of funding instrument. The grant does not require cost sharing or matching. The purpose of this funding opportunity is to examine the utility of an in vitro simulated gastrointestinal (GI) dissolution model for the assessment of in vitro performance of amorphous solid dispersion (ASD) drug products under different clinically relevant conditions. The goal is to develop and validate the in vitro mechanistic methodology to provide an improved understanding of the impact of food and acid reducing agents on the absorption for test and reference listed drug (RLD) drug products, taking into consideration their potentially different formulations and manufacturing. The bio predictive in vitro mechanistic methodology is intended to correlate the in vitro observations to in vivo outcomes, help define types of in vivo bioequivalence (BE) studies needed for ASD drug products, and inform regulatory decision-making related to mitigating the risk of potential failure modes for therapeutic equivalence for high-risk generic oral drug products. The grant has an award ceiling of $500,000 and an award floor of $250,000. It is expected that there will be 2 awards given. The eligible applicants for this grant opportunity are unrestricted, meaning any applicant organization may submit an application. However, each application must be scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time. For more information and to apply for this grant opportunity, you can contact Terrin Brown, the Grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610. The last updated date for this grant opportunity is November 30, 2023.
Critical Path Public Private Partnerships Clinical Trials Optional
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is seeking an application for the Critical Path Public Private Partnerships Clinical Trials. This grant opportunity is part of the Critical Path Initiative introduced in Section 566 of the Federal Food, Drug, and Cosmetic Act. The FDA aims to maintain and manage existing consortia groups established by the Critical Path Institute. The funding will support the development of innovative and collaborative projects in research, education, and outreach to foster drug product innovation. The goal is to accelerate development, manufacturing, and translational therapeutics while enhancing safety, efficacy, quality, and performance. The grant amount is set at $20,000,000, and there is expected to be one award. The funding does not require cost sharing or matching. The eligible applicant for this opportunity is the Critical Path Institute. For more information, you can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610.
Collaborations to Enhance Drug Development and Regulatory Science
Active
Food and Drug Administration
The Food and Drug Administration (FDA) is offering a grant opportunity titled "Collaborations to Enhance Drug Development and Regulatory Science". This grant aims to support, manage, and facilitate Public-Private Partnerships and Collaborative activities as part of the Critical Path Initiative and to support regulatory science efforts. The FDA and grantees will work together to develop innovative, collaborative projects in research, education, and outreach. These projects can help foster drug product innovation by supporting efforts to accelerate drug product development, approaches to advanced manufacturing, translation of basic science discoveries into therapeutics, and approaches to enhance the safety, efficacy, quality, and performance of drug products. The grant has an award ceiling and floor of $5,000,000 and expects to fund 6 awards. The grant is forecasted and falls under the category of funding activity for Consumer Protection. The grant is open to unrestricted eligible applicants. The deadline for application submission is in the fiscal year 2024. For more information, you can contact Terrin Brown, the grantor, at terrin.brown@fda.hhs.gov or (240) 402-7610.